The US arm of the company, Lupin Pharmaceuticals Inc, has launched Amlodipine and Valsartan tablets in various strengths in the US market after getting final approval from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
Lupin's Amlodipine and Valsartan tablets are indicated for the treatment of hypertension and to lower blood pressure and is the generic version of Novarts Pharmaceuticals Corporation's Exforge tablets.
As per IMS MAT sales data, Exforge tablets had US sales of USD 414.9 million.
Lupin shares were trading at Rs 2,033 a piece on the BSE, up 1.29 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%